Explore / Clinical trial
Clinical trial

Covid-19 Vaccine Immune Response in Multiple Sclerosis

University Hospitals of North Midlands NHS TrustActive, not recruitingStarted Feb 16, 2022240 enrolledUnited KingdomNCT05269888

Abstract

Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection. While these vaccines have been offered to people with multiple sclerosis (MS), they have not been tested in these individuals. It is uncertain whether people with MS will develop protective antibodies after a Covid-19 vaccination and how long these antibodies will last. The investigators are planning to study the immune response to the full course of Covid-19 vaccine in people with MS (study group) and compare this to people without MS or immune suppression (control group).

Keywords

Multiple Sclerosis

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.